statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dr. Reddy's Considers Stock Split Proposal

Dr Reddy's Laboratories (RDY) has released an update. Dr. Reddy's Laboratories has announced that its Board of Directors will consider a proposal t...

Dr. Reddy's Q1FY25 Financial Results Imminent

Dr Reddy's Laboratories (RDY) has released an update. Dr. Reddy's Laboratories, a global pharmaceutical company, has announced its Q1FY25 financial...

Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M

Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for 500 million ($632 million). This strategic move allows Haleon to focus on...

Dr. Reddys to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as Dr. Reddys), a global pharmaceutical company, today announced...

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities

Aurigene Pharmaceutical Services Limited (Aurigene), a Dr. Reddys Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located...

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as 'Dr. Reddy's'), today announced the appointment of Milan...

Alvotech and Dr. Reddys Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia & Xgeva in the U.S., Europe and UK

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddys Laboratories SA...

Dr. Reddys Q4 & Full Year FY24 Financial Results

Dr. Reddys Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024...

Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as 'Dr. Reddy's'), today announced its launch of Doxycycline...

StockNews.com Upgrades Dr. Reddy's Laboratories (NYSE:RDY) to "Strong-Buy"

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) was upgraded by equities research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report issued on Friday.
Several...

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Volume	250,264.00
52-Wk High	$81.98
52-Wk Low	$63.72

RDY Dr. Reddy's Laboratories Ltd.

About

Feed

News

Sentiment

Earnings

Fundamentals